PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.

Abstract

BACKGROUND:

The PRAME (preferentially expressed antigen of melanoma) gene is frequently overexpressed in a wide variety of malignant diseases, including acute myeloid leukemia (AML) and acute B-cell malignancies.

AIM:

To study the expression of PRAME gene and clarify its prognostic impact on disease outcome.

METHODS:

Screening for PRAME gene expression was assessed using real-time reverse transcriptase polymerase chain reaction in 55 pretreated ALL bone marrow samples.

RESULTS:

PRAME positivity was found in 14 (31.3%) of 45 patients. No significant correlation could be observed between PRAME expression and clinical characteristics. Positive PRAME expressers had a statistically higher CR (p = 0.001), lower relapse (p = 0.02), lower mortality (p < 0.001), a trend towards lower Refractory disease (p = 0.10), and a statistically longer DFS and OS (p < 0.001, < 0.001, respectively) in comparison to negative PRAME expressers.

CONCLUSIONS:

Our results suggested that PRAME was a predictor for better outcome, could be a useful target for immunotherapy, and might represent a candidate marker for the monitoring of minimal residual disease.

• Authors: C A Abdelmalak, R S Yahya, D M Elghannam, A E El-Khadragy, H M Abd El Messih
• Journal: Clinical laboratory (Clin Lab) Vol. 60 Issue 1 Pg. 55-61 ( 2014) ISSN: 1433-6510 [Print] Germany
• PMID: 24600975 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• DNA Primers
• PRAME protein, human

Topics

• Antigens, Neoplasm (genetics)
• Base Sequence
• Child
• DNA Primers
• Female
• Humans
• Male
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, pathology)
• Prognosis
• Real-Time Polymerase Chain Reaction
• Reverse Transcriptase Polymerase Chain Reaction